Lisdexamfetamine Dimesylate Tablet, Chewable
Product Images NDC 70010-218

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Lisdexamfetamine Dimesylate (NDC 70010-218). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Granules Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Lisdexamfetamine-10mg-100s (Lisdexamfetamine 10mg 100s)

Label for Lisdexamfetamine Dimesylate Chewable Tablets 10 mg by Granules Pharmaceuticals Inc. The label states it contains 100 chewable tablets, each with 10 mg lisdexamfetamine dimesylate (5.8 mg lisdexamfetamine equivalent). It includes storage instructions, a pharmacist dispensing note, and a barcode. Lot and expiration date fields are blank.*

FDA Label Image

Lisdexamfetamine-20mg-100s (Lisdexamfetamine 20mg 100s)

Label for Lisdexamfetamine Dimesylate Chewable Tablets, 20 mg strength, manufactured by Granules Pharmaceuticals Inc. The label states each chewable tablet contains 20 mg lisdexamfetamine dimesylate, equivalent to 11.6 mg lisdexamfetamine. The package includes 100 chewable tablets and instructs to chew completely before swallowing, not to swallow whole tablets. It notes storage temperature ranges and dispensing guidelines with a child-resistant closure.*

FDA Label Image

Lisdexamfetamine-30mg-100s (Lisdexamfetamine 30mg 100s)

Label for Lisdexamfetamine Dimesylate Chewable Tablets 30 mg by Granules Pharmaceuticals Inc. The label indicates the product is a prescription chewable tablet with 100 tablets per container. It includes storage instructions, dispensing requirements, and a lot and expiration date section. The NDC number is 70010-216-01.*

FDA Label Image

Lisdexamfetamine-40mg-100s (Lisdexamfetamine 40mg 100s)

Lisdexamfetamine Dimesylate Chewable Tablets 40 mg label for oral use, containing 100 chewable tablets. The label indicates the product is a Schedule II prescription drug manufactured by Granules Pharmaceuticals Inc. Storage instructions specify 20° to 25°C with permitted excursions. The label includes dispensing instructions and a barcode.*

FDA Label Image

Lisdexamfetamine-50mg-100s (Lisdexamfetamine 50mg 100s)

Label for Lisdexamfetamine Dimesylate Chewable Tablets 50 mg by Granules Pharmaceuticals Inc. The label states the product contains 100 chewable tablets and includes storage instructions and pharmacist dispensing guidance. It notes to chew tablets completely before swallowing and provides a website for medication guides. The label includes NDC 70010-218-01 and a barcode.*

FDA Label Image

Lisdexamfetamine-60mg-100s (Lisdexamfetamine 60mg 100s)

Label for Lisdexamfetamine Dimesylate Chewable Tablets 60 mg by Granules Pharmaceuticals Inc. The label states the tablets are chewable, with 100 tablets per container. It includes storage instructions, dispensing guidelines, dosage information references, and a barcode. The label also advises to chew tablets completely and not swallow whole.*

FDA Label Image

Lisdexamfetamine-fig1 (Lisdexamfetamine Fig1)

A pharmacokinetic chart illustrating fold change and 90% confidence intervals for Cmax and AUC parameters in special populations, including male/female gender, age groups 65-74 years and 75 years or older, and varying degrees of renal impairment (mild, moderate, severe, and end stage renal disease). The x-axis represents change relative to reference from 0.0 to 2.5.*

FDA Label Image

Lisdexamfetamine-fig2 (Lisdexamfetamine Fig2)

A forest plot showing the fold change and 90% confidence intervals for the pharmacokinetic parameters Cmax and AUC of guanfacine, venlafaxine, and omeprazole relative to a reference. The x-axis represents change relative to reference from 0.0 to 2.0, with data points and error bars for each drug and parameter.*

FDA Label Image

Lisdexamfetamine-fig3 (Lisdexamfetamine Fig3)

A pharmacokinetic (PK) scatter plot showing fold change and 90% confidence intervals (CI) for various interacting drugs with lisdexamfetamine dimesylate. The chart compares Cmax and AUC values for drugs including Guanfacine, Venlafaxine, Caffeine (CYP1A2 substrate), Dextromethorphan (CYP2D6 substrate), Omeprazole (CYP2C19 substrate), and Midazolam (CYP3A substrate), relative to a reference value of 1.0 with a range from 0.0 to 2.0 on the x-axis.*

FDA Label Image

Lisdexamfetamine-fig4 (Lisdexamfetamine Fig4)

A line graph depicting LS Mean (SE) SKAMP Deportment Scores over time post-dose (hours) comparing Lisdexamfetamine Dimesylate and placebo. The graph shows SKAMP scores on the y-axis and time in hours on the x-axis, illustrating differing score trends between the two groups over approximately 13 hours.*

FDA Label Image

Lisdexamfetamine-fig5 (Lisdexamfetamine Fig5)

A Kaplan-Meier survival curve showing the proportion of subjects with relapse or temperature failure over time after randomization. The graph compares two groups: one receiving Lisdexamfetamine dimesylate (solid line) and one receiving placebo (dashed line). The y-axis represents the percentage of affected subjects, and the x-axis shows days after randomization up to 55 days.*

FDA Label Image

Lisdexamfetamine-fig6 (Lisdexamfetamine Fig6)

A line graph comparing LS Mean (SE) PERMP Total Scores over Time Post-Dose (hours) between Lisdexamfetamine Dimesylate and Placebo. The graph shows score trends from just before dosing to 14 hours post-dose, with separate lines for Lisdexamfetamine Dimesylate and Placebo, including error bars indicating variability at each time point.*

FDA Label Image

Lisdexamfetamine-fig7 (Lisdexamfetamine Fig7)

A Kaplan-Meier survival curve chart comparing the proportion of subjects with relapse or treatment failure over time (days after randomization). Two groups are shown: placebo (dotted line) and lisdexamfetamine dimesylate (solid line). The chart tracks relapse rates up to 35 days, with the placebo group showing a higher proportion of relapse compared to the lisdexamfetamine dimesylate group.*

FDA Label Image

Lisdexamfetamine-fig8 (Lisdexamfetamine Fig8)

A line graph depicting the proportion of subjects experiencing release (%) over time (days after randomization) for Lisdexamfetamine dimesylate compared to placebo. The graph shows a near-zero release proportion for Lisdexamfetamine dimesylate and a gradually increasing proportion for placebo, with subject counts decreasing over time for both groups.*

FDA Label Image

Lisdexamfetamine-structure (Lisdexamfetamine Structure)

Chemical structure of lisdexamfetamine dimesylate, showing the molecular arrangement of its atoms and functional groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.